LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF

Disclosed herein are liquid pharmaceutical formulations comprising levodopa amino acid conjugates that may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generativ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BRAIMAN-WIKSMAN, Liora, MAINFELD, Alex, NAKAO, Akira, OKUNO, Masataka, GAZAL, Elana, SHALTIEL-KARYO, Ronit, IIJIMA, Daisuke, ZAWOZNIK, Eduardo, BEN-HAMO, Shmuel, MOROKUMA, Kenji
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Disclosed herein are liquid pharmaceutical formulations comprising levodopa amino acid conjugates that may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed liquid pharmaceutical formulations. Disclosed also are LDAA conjugate compounds. Cette invention concerne des formulations pharmaceutiques liquides comprenant des conjugués d'acides aminés de lévodopa qui peuvent en outre comprendre un inhibiteur de la décarboxylase, tel que la carbidopa, un antioxydant, un solvant, ou tout autre excipient pharmaceutiquement acceptable. L'invention concerne en outre des procédés de traitement de maladies dégénératives et/ou de maladies caractérisées par des niveaux réduits de dopamine dans le cerveau, telle que la maladie de Parkinson, comprenant l'administration des formulations pharmaceutiques liquides décrites. L'Invention concerne également des composés conjugués de LDAA.